SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted

Drug makers have rolled out a flurry of sodium glucose co-transporter-2 (SGLT-2) inhibitors (six compounds/seven products) in Japan over a 10-month period, hoping to see them follow a successful class of dipeptidyl peptidase-4 (DPP-4) inhibitors. However, their sales performances have...read more